<DOC>
	<DOCNO>NCT01211873</DOCNO>
	<brief_summary>The purpose study look safety ( side effect ) efficacy ( well work ) Dotarem® use take image brain / spine . The result compare result MRI take without Dotarem .</brief_summary>
	<brief_title>Safety Efficacy Evaluation DOTAREM® MRI Central Nervous System ( CNS ) Lesions</brief_title>
	<detailed_description>This study involve use Magnetic Resonance Imaging ( MRI ) contrast agent call Dotarem® . The purpose study look safety ( side effect ) efficacy ( well work ) Dotarem® use take image brain spine . The result MRI compare result image take without Dotarem® .</detailed_description>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N , N ' , N '' , N '' '-tetraacetate</mesh_term>
	<criteria>Adult subject pediatric subject ( age great equal two ( 2 ) year ) . Is refer contrastenhanced MRI CNS base result previous imaging procedure . Female childbearing potential patient must effective contraception ( contraceptive pill intrauterine device ) surgically sterilize postmenopausal ( minimum 12 month amenorrhea ) , document negative urine pregnancy test within 24 hour prior study MRI . Has fully inform study , consent participate . Having acute chronic grade IV V renal insufficiency . Known class III/IV congestive heart failure . Suffering long QT syndrome . Unstable health condition circumstance ( e.g . suffer severe claustrophobia ) . Having contraindication MRI pacemaker , magnetic material condition would preclude proximity strong magnetic field . Known allergy Gadolinium chelate . Having receive contrast agent within 3 day prior study contrast administration , schedule receive contrast agent within 24 hour study contrast administration . Pregnant , breast feeding , plan become pregnant trial . Previously participate trial . Having participate within 30 day another clinical trial involve investigational drug . Any condition , base investigator 's clinical judgement , would prevent patient complete trial assessment visit . Inability unwillingness cooperate requirement trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CNS</keyword>
	<keyword>Contrast Agent</keyword>
	<keyword>MRI</keyword>
	<keyword>Dotarem</keyword>
	<keyword>Magnevist</keyword>
</DOC>